It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
IL-2 is the master-regulator cytokine for T cell dependent responses and is crucial for proliferation and survival of T cells. However, IL-2-based treatments remained marginal, in part due to short half-life. Thus, we aimed to extend IL-2 half-life by flanking the IL-2 core with sequences derived from the extensively glycosylated hinge region of the NCR2 receptor. We termed this modified IL-2: “S2A”. Importantly, S2A blood half-life was extended 14-fold compared to the clinical grade IL-2, Proleukin. Low doses inoculation of S2A significantly enhanced induction of Tregs (CD4+ Regulatory T cells) in vivo, as compared to Proleukin, while both S2A and Proleukin induced low levels of CD8+ T cells. In a B16 metastatic melanoma model, S2A treatment was unable to reduce the metastatic capacity of B16 melanoma, while enhancing induction and recruitment of Tregs, compared to Proleukin. Conversely, in two autoimmune models, rheumatoid arthritis and DSS-induced colitis, S2A treatment significantly reduced the progression of disease compared to Proleukin. Our results suggest new avenues for generating long-acting IL-2 for long-standing treatment and a new technique for manipulating short-life proteins for clinical and research uses.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Ben-Gurion University of the Negev, The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Beer Sheva, Israel (GRID:grid.7489.2) (ISNI:0000 0004 1937 0511); Ben-Gurion University of the Negev, National Institute for Biotechnology in the Negev, Beer Sheva, Israel (GRID:grid.7489.2) (ISNI:0000 0004 1937 0511)
2 Ben-Gurion University of the Negev, The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Beer Sheva, Israel (GRID:grid.7489.2) (ISNI:0000 0004 1937 0511)
3 Ben-Gurion University of the Negev, Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Beer Sheva, Israel (GRID:grid.7489.2) (ISNI:0000 0004 1937 0511)